Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KER-047 in Functional Iron Deficiency Anemia in MDS/MF
NCT05927012Phase 2Withdrawn
- Sponsor
- Keros Therapeutics
- Start
- Nov 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of KER-047 in iron deficiency anemia (IDA), myelodysplastic syndrome (MDS), myelofibrosis (MF), myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by Keros Therapeutics. Planned start Nov 2023; status: withdrawn.
02
Drugs
KER-047
03
Conditions
iron deficiency anemia (IDA)myelodysplastic syndrome (MDS)myelofibrosis (MF)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT05927012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05927012.